Remdesivir Global Market Report 2023 – By Route Of Administration (Oral, Intravenous), By Dosage Form (Tablets, Frozen Solution, Lypholized Solution), By Distribution Channel (Hospitals, Clinics, Drug Stores/Pharmacies, Online, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2023-2032

Coronavirus (COVID-19) current therapy refers to a drug created and used to treat mild to moderate COVID-19 in those who have a higher risk of experiencing significant illness as a result of COVID-19. The main types of drugs in coronavirus (COVID-19) current therapy are redeliver, hydroxychloroquine, ritonavir, lopinavir, interferon beta, and others. Remdesivir is an antiviral drug that works by preventing an RNA-based virus from replicating its viral genome within an infected cell. It was first used to combat the Ebola virus. It can be administered through various routes such as oral and intravenous. The different sectors include hospitals, clinics, and research institutes; others. The global coronavirus (COVID-19) current therapy market is segmented - 1) By Drug Type: Remdesivir, Hydroxychloroquine, Ritonavir, Lopinavir, Interferon Beta, Other Drug Type 2) By Route Of Administration: Oral, Intravenous 3) By End User: Hospitals, Clinics, Research Institutes, and Other End Users The global coronavirus (covid-19) current therapy market size grew from $16.43 billion in 2022 to $11.73 billion in 2023 at a compound annual growth rate (CAGR) of -28.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of the global coronavirus (covid-19) current therapy market is expected to grow to $1.05 billion in 2027 at a CAGR of -45.3%. The outbreak of the pandemic COVID-19 contributed to the growth of the coronavirus (COVID-19) current therapy market. On March 11, 2020, the World Health Organization (WHO) declared the outbreak a global pandemic. According to the World Health Organization (WHO), there were 10,719,946 cases of COVID-19, including 517,337 deaths reported to the WHO on July 3, 2020, and this number is expected to grow soon. As there is no officially approved drug for COVID-19, the demand has risen significantly for repurposed drugs that are used for corona therapy. Countries across the world are facing shortages of drugs, and drug manufacturers are ramping up production to meet the global demand. The Coronavirus Treatment Acceleration Program (CTAP) is a special emergency programme initiated by the FDA for the development of potential COVID-19 therapies to be made available to patients as quickly as possible. Major players in the coronavirus (COVID-19) current therapy market report are Moderna Therapeutics, Novavax, Bravovax, Ascletis Pharma, Altimmune, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Inc., Biocryst Pharma, Gilead Sciences, and Regeneron Pharmaceuticals. High costs involved in the research and development of therapeutic drugs and vaccines and the long waiting time required for each phase of clinical trials are expected to limit the growth of the coronavirus (COVID-19) current therapy market. According to a recent study published in the Journal of Health Economics by the Tufts Center for the Study of Drug Development, it is estimated to cost $2.6 billion in developing a new prescription medicine and gain marketing approval, and seven out of eight pipeline drugs will fail in the development process. Moreover, the time required for each phase of the clinical trial and drug approval process takes an average of 12 years for an experimental drug to reach the market. High costs and long waiting times for drug development are expected to hamper the coronavirus (COVID-19) current therapy market growth. Convalescent Plasma Therapy is used as an experimental therapy to treat COVID-19 patients. The blood plasma of patients who have recovered from a disease is called convalescent plasma (CP). Convalescent plasma therapy (CP) is a type of passive antibody therapy in which blood plasma is isolated from patients who have recovered from the disease of interest and administered to a patient with severe disease in order to suppress virulence and improve clinical symptoms. The blood plasma of recovered COVID-19 patients has antibodies to fight COVID-19 infection. According to guidance issued by the FDA, Convalescent Plasma Therapy is recommended as an investigational product during a public health emergency. By 30th April 2020, around 2,004 participating sites adhering to a single expanded access protocol by the US FDA had been registered, around 7,774 patients have enrolled, and 3,809 of them have undergone convalescent plasma transfusion. The experimental convalescent plasma therapy is likely to gain attention if enough data is supporting the results. In March 2020, Sanofi and Regeneron Pharmaceuticals planned to initiate clinical trials of the rheumatoid arthritis drug Kevzara (sarilumab) for the treatment of COVID-19 symptoms. The US Food and Drug Administration (FDA) approved Kevzara to treat rheumatoid arthritis. The drug is part of an ongoing antibody partnership between Sanofi and Regeneron. Kevzara is a fully-human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway by binding and blocking the IL-6 receptor. IL-6 may play a role in driving the overactive inflammatory response in the lungs of patients who are severely or critically ill with COVID-19. Following a review by the Independent Data Monitoring Committee (IDMC) of all available Phase 2 and Phase 3 data, the trial will be immediately amended so that only critical patients continue to be enrolled to receive Kevzara 400 mg. North America is the largest region in the coronavirus (COVID-19) current therapy market in 2022. Middle East is expected to be the fastest growing region in the global coronavirus (COVID-19) current therapy market share during the forecast period. The regions covered in the coronavirus (COVID-19) current therapy market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the coronavirus (COVID-19) current therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The coronavirus (COVID-19) current therapy market includes revenues earned by entities by tocilizumab, favipiravir, and ivermectin. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The coronavirus (COVID-19) current therapy market research report is one of a series of new reports from The Business Research Company that provides coronavirus (COVID-19) current therapy market statistics, including coronavirus (COVID-19) current therapy industry global market size, regional shares, competitors with a coronavirus (COVID-19) current therapy market share, detailed coronavirus (COVID-19) current therapy market segments, coronavirus (COVID-19) current therapy market trends and opportunities, and any further data you may need to thrive in the coronavirus (COVID-19) current therapy industry. This coronavirus (COVID-19) current therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Cell culture is a process for developing substrates for the safe production of viral vaccines. 3D cell culture is an in vitro technique wherein the cells can grow in an artificially created environment. The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The main types of 3D cell culture technologies are scaffold-based, scaffold-free, and 3D bioreactors. The 3D bioreactors are small plastic cylinder chambers designed specifically for growing cells in three dimensions. The various scaffold-based technologies include hydrogels, polymeric scaffolds, micropatterned surface microplates and the different scaffold-free technologies are hanging drop microplates, spheroid microplates, microfluidic 3d cell culture, magnetic levitation and 3D bioprinting. The technologies are applied for cancer research, stem cell research, drug discovery, and regenerative medicine that are used by research laboratories and institutes, biotechnology and pharmaceutical companies, hospitals and diagnostic centers, and other end users. The global 3D cell culture technologies market is segmented – 1) By Type: Scaffold-based, Scaffold-free, 3D Bioreactors 2) By End Users: Research Laboratories and Institutes, Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostic Centers, Other End Users 3) By Scaffold-based: Hydrogels, Polymeric scaffolds, Micropatterned Surface Microplates 4) By Scaffold-free: Hanging Drop Microplates, Spheroid Microplates, Microfluidic 3D Cell Culture, Magnetic Levitations & 3D Bioprinting 5) By Application: Cancer Research, Stem Cell Research, Drug Discovery, Regenerative Medicine The global 3d cell culture technologies market size grew from $2.39 billion in 2022 to $2.83 billion in 2023 at a compound annual growth rate (CAGR) of 18.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the 3d cell culture technologies market is expected to grow from $5.65 billion in 2027 at a CAGR of 18.9%. The increasing requirement for organ transplantation is driving the 3D Cell Culture Technologies Market. 3D cell culture helps in forming a three-dimensional structure which further helps in mimicking the tissue or organ and therefore helps in organ transplantation. 3D cell structures are capable of tissue and organ regeneration as well as providing the provision for drug toxicology screening. For instance, according to the Organ Procurement and Transplantation network, an American non-profit organization administering the organ transplantation in the US, 41,354 organ transplantations were performed in the United States in 2021 which was an increase of 5.9% as compared to 2020 and the number exceeded 40,000 mark for the first time ever. Major players in the 3D cell culture technologies market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Lonza, HiMedia Laboratories, Agilent Technologies, PromoCell GmbH, CellGenix GmbH, InvivoGen, Greiner Bio-One, Irvine Scientific, Cell Culture Company (CCC) LLC., Sera Care Life Sciences Incorporation, American Type Culture Collection, Miltenyi Biotec, AITbiotech, ESSEN, Sigma-Aldrich, Bel-Art, MilliporeSigma, Cellgenix, Sumitomo Bakelite, EMD Millipore, AffymetrixInc., VWR International, LLC., WHEATON IndustriesInc., and Sartorius A. The possibility of contaminating the cells is restricting the 3D Cell Culture technologies market. Contamination of the cell culture refers to the presence of bacteria, moulds, yeasts, viruses, and mycoplasma that can adversely affect the cell culture. Contamination usually occurs when the cells are mishandled or due to the lack of adequate care, as a result the process of regeneration may get affected. According to a study conducted by Yale and Tuff's university, it was found that 3D cultures are more complex than 2D cell cultures and they require a more controlled cellular environment in order to mimic structures for tissue or organ transplants. Therefore, probability of cell culture contamination is relatively higher in 3D cell cultures. Implementing the latest technology is the latest trend in the 3D Cell culture market. For example, various companies have adopted one such advancement in the market for 3D cell culture, this is the use of the vivo/vitro environment. Cell expansion and interactions under 2D are not appropriate in vitro models but when compared with 3D cell culture technique, it offers a better cell culture environment. The Vitro environment enables researchers or doctors to conduct the procedure in a controlled environment outside the organism. This procedure is gaining importance as it plays a vital role in monitoring the health of patients. FDA approved Biotek's 3D cell expansion system to be used as a medical device. It also approved Biotek's Polycaprolactone (PCL) which is a biodegradable polyester material that is used in many FDA-approved implants and drug delivery devices. FDA regulates the cell culture technologies under title 21, sec 864.2240. FDA states that cell and tissue culture technologies should be labelled or mentioned as sterile, or else they would be removed from the good manufacturing practice of the quality system. Each technology unit should maintain procedures to receive, review, and evaluate complaints. These procedures should also include consistent documentation of the receipts. In May 2021, CELLINK Group, a USA-based start-up that designs and supplies technologies and services to enhance biology research, has acquired Visikol Corporation for $7.5 million. With this acquisition, CELLINK made an entrance into the contract research market. Visikol Corp., an American contract research services company that provides pharma and biotech industries with leading services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology. North America was the largest region in the 3D cell culture technologies market in 2022. Western Europe was the second largest region in the 3D cell culture technologies market share. The regions covered in the global 3D cell culture technologies market report analysis are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the 3D cell culture technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The 3D cell culture technologies market consists of sales of 3D cell culture technologies such as microfluidics, hydrogels scaffolds, scaffold-free 3D cell culture techniques, spheroids, cube, spherical droplet, stacked plate, magnetic bead, organ-on-chips and other technologies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The 3D cell culture technologies market research report is one of a series of new reports from The Business Research Company that provides 3D cell culture technologies market statistics, including 3D cell culture technologies industry global market size, regional shares, competitors with a 3D cell culture technologies market share, detailed 3D cell culture technologies market segments, market trends and opportunities, and any further data you may need to thrive in the 3D cell culture technologies industry. This 3D cell culture technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell culture consumables and equipment are designed to aid scientists in growing new cells in the culture media for drug development, tissue culture, engineering, gene therapy, vaccine production, and toxicity testing. The main products in cell culture consumables and equipment are consumables and instruments. The cell culture instruments involve the various instruments that are required for cell culture in the cell culture laboratory. The various instruments used in cell culture are cell culture vessels, bioreactors, biosafety cabinets, carbon dioxide incubators, and centrifuge and consumables are media, sera, and reagents. The applications involved are vaccination, toxicity testing, cancer research, drug screening and development, recombinant products, stem cell technology, regenerative medicine, and others that are used by end-users such as industrial, biotechnology, agriculture, and others. The global is segmented - 1) By Product: Consumables, Instruments 2) By End User: Industrial, Biotechnology, Agriculture, Other End Users 3) By Application: Vaccination, Toxicity testing, Cancer Research, Drug Screening and Development, Recombinant Products, Stem cell technology, Regenerative Medicine, Other End Users 4) By Consumables: Media, Sera, Reagents 5) By Instruments: Cell Culture Vessels, Bioreactors, Biosafety Cabinets, Carbon Dioxide Incubators, Centrifuges The global cell culture consumables and equipment market grew from $10.99 billion in 2022 to $12.12 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the cell culture consumables and equipment is expected to grow from $17.98 billion in 2027 at a CAGR of 10.4%. An increase in the prevalence of chronic diseases is driving the growth of the cell culture consumables and equipment market. Chronic diseases such as cancer, diabetes, heart diseases, obesity, and hypertension are growing rapidly. A few chronic diseases are caused due to loss or damage of certain types of cells. Such diseases can be cured by replacing the destroyed cells with new ones that are produced by pluripotent stem cells, using cell culture consumables and equipment. So, with the rising incidence of chronic diseases, there is an increased need for such equipment that can produce new cells outside the natural environment, thus driving the growth of this market. For example, according to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. Major players in the cell culture consumables and equipment market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Lonza, HiMedia Laboratories, Agilent Technologies, and PromoCell GmbH. Contamination of cell culture is the most prominent factor restricting the growth of cell culture consumables and equipment market. Contaminated culture is the presence of non-living substances or unwanted foreign microorganisms that have undesirable effects on the cell culture. Using contaminated culture cells has several negative consequences on the users and thus hampers the growth of this market. For example, an article published on MedCrave, stated that Mycoplasma is one of the most common and difficult to detect contaminants. The article also highlighted the results of a study on fibroblasts and keratinocyte cell lines that showed 32.35% of contamination, out of which 17.65% were mycoplasma contaminated cultures, followed by fungal (8.82%) and bacterial (5.88%) contaminants. Hence, the high risk associated with cell culture techniques poses a threat to the growth of the cell culture consumables and equipment market. Companies in cell culture consumables and equipment are investing more in 3D cell culture for its new and advantageous features. 3D cell culture may be defined as the culture of living cells within micro-assembled devices and supports that present a three-dimensional structure and are used to replicate a tissue or an organ in an artificial environment by allowing the cells to interact with the surroundings in all three directions. 3D cell cultures are more relevant with a higher degree of structural complexity and maintain the steady-state for more time as compared to 2D cell cultures. In August 2021, Amerigo Scientific, a US-based manufacturer of biomedical and life sciences products, launched #D cell cultures for research purposes. FDA regulates cell culture consumables and equipment in the U.S. Under title 21, Sec 864.2240. For cell and tissue culture equipment, the FDA states that if the equipment is not labelled or mentioned as sterile, it would be removed from the good manufacturing practises of the quality system. Additionally, each manufacturing unit should maintain procedures to receive, review, and evaluate complaints. These procedures require consistency and punctuality, along with the documentation of the receipts. Therefore, these regulatory standards improve the safety and efficacy of instruments and consumables used during cell culture processes. In July 2021, Sartorius, a Germany-based laboratory instrument manufacturer, acquired Xell AG for an undisclosed amount. The acquisition would expand Sartorius’ current media offering and other cell culture products. Xell AG is a Germany-based cell culture specialist. North America was the largest region in the cell culture consumables and equipment market in 2022. Western Europe was the second largest region in the global cell culture consumables and equipment market share. The regions covered in the global cell culture consumables and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell culture consumables and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell culture consumables and equipment market consists of sales of flasks, tubes, dishes or cryovials, serological pipettes or centrifugation tubes, bottles, cell scrapers, strainers, coverslips, and inserts. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The cell culture consumables and equipment market research report is one of a series of new reports from The Business Research Company that provides cell culture consumables and equipment market statistics, including cell culture consumables and equipment industry global market size, regional shares, competitors with a cell culture consumables and equipment market share, detailed cell culture consumables and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cell culture consumables and equipment industry. This cell culture consumables and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Metabolomics is a branch of bio-analytics that deals with the quantification and identification of metabolic small molecules found in cells, tissues, organs, and biological fluids.Research in the area of metabolomics focuses on the chemical reactions that metabolites go through. The main products and services of metabolomics are metabolomics instruments, metabolomics bioinformatics tools, and services. Metabolomics instruments are devices used to extensively examine low-molecular-weight compounds in biological samples. The various metabolomics instruments include separation techniques, detection techniques, and metabolomics bioinformatics tools and services involving bioinformatics tools and databases, as well as bioinformatics services. The different indications are cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others that are applied in biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and others. The global metabolomics market is segmented - 1) By Product & Service: Metabolomics Instruments, Metabolomics Bioinformatics Tools & Services 2) By Application: Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics, Personalized Medicine, Other Applications 3) By Indication: Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Errors of Metabolism, Other Indications 4) By Metabolomics Instruments: Separation Techniques, Detection Techniques 5) By Metabolomics Bioinformatics Tools & Services: Bioinformatics Tools and Database, Bioinformatics Services The global metabolomics market size will grow from $2.69 billion in 2022 to $3.09 billion in 2023 at a compound annual growth rate (CAGR) of 14.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of the global metabolomics market is expected to grow to $5.61 billion in 2027 at a CAGR of 16.1%. The increasing prevalence rate of cancer drives the metabolomics market growth. Metabolomics screens the potential biomarkers (specific cells, molecules, or genes, gene products, enzymes, or hormones) to measure the cancer drug responsiveness aiding early diagnosis. For instance, according to a report by WebMD,an American publisher of health related news, in 2021, 10 million people died of cancer worldwide. In 2020, according to the American Cancer Society, lung cancer is the leading cancer killer in both men and women in the USA, there were 228,820 new cancer cases and 135,720 deaths. Metabolomics approaches such as nuclear magnetic resonance (NMR) technique and mass spectrometry (MS) techniques have been used to study cancer. Companies like Metabolon Inc., Bruker Corp., and others have adopted metabolomics as a tool for early detection and cure for cancer. Major players in the metabolomics market report are Human Metabolome Technologies, Metabolon, Bio-Rad Laboratories, Bruker, Agilent Technologies, Thermo Fisher, Waters, Biocrates Life Sciences, Shimadzu, Danaher Corporation, Kore Technologies Ltd., Dani Instruments S.P.A, Perkinelmer Inc., Evans Analytical Group LLC., LECO Corporation, Phenomenome Discoveries Inc., AB Sciex, BG Medicine Inc., Biomark Diagnostics Inc., Chenomx Inc., Creative Proteomics, Evotec A.G, and Merck kgaA 3d. The increasing complexity in interpreting data act as a restraint hindering the metabolomics market growth. Metabolomics tools generate huge quantum of data through metabolomics techniques and the generated data keeps changing not static, hence increasing the difficultly in interpretation of data. For instance, data generated by nuclear magnetic resonance (NMR) Spectroscopy, an analytical technique used for metabolic profiling (a method to measure and interpret various low molecular weight and other intermediates), is difficult to process and interpret. High-level statistical techniques are required for classification and analysis of this data to uncover the biological knowledge which is time-consuming and expensive, restraining the metabolomics market growth. Machine learning is increasing its popularity in the field of metabolomics due to improving efficiency in the interpretation of data generated from metabolomics techniques. Machine learning-enabled technologies help in the automation of risky and complex processes, avoid repetitive and time taking processes, provide quick and error-free services. Companies in the industry are preferring machine learning techniques for metabolism analysis to solve problems, automate processes and execute tasks. Some of the machine learning algorithms aid in metabolism data analysis and metabolic pathway modelling. Some of the companies such as Bio-Rad Laboratories, Metabolon Inc. and others have started using machine learning algorithms for better understanding and prediction in metabolomics study. For instance, MeltDB 2.0, a machine learning software used as a tool for the analysis and integration of metabolomics experiment data that aids research, store experimental data sets. Such machine learning software offer comprehensive analysis and visualization features for the proper representation of the large complex data. In Clinical Microbiomics, a Denmark-based microbiome research company, acquired MS-Omics for an undisclosed amount. The acquisition added specialized metabolic profiling offerings to its portfolio, which will advance its systems biology platform and help researchers all around the world. MS-Omics is a Denmark-based metabolomics company. North America was the largest region in the metabolomics market in 2022. Western Europe was the second largest region in the global metabolomics market share. The regions covered in the metabolomics industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the metabolomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The metabolomics market includes revenue earned by liquid chromatography, gas chromatography, capillary electrophoresis, mass spectrometry, and nuclear magnetic resonance spectroscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The metabolomics market research report is one of a series of new reports from The Business Research Company that provides metabolomics market statistics, including metabolomics industry global market size, regional shares, competitors with a metabolomics market share, detailed metabolomics market segments, market trends and opportunities, and any further data you may need to thrive in the metabolomics industry. This metabolomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Induced pluripotent stem cells are the regenerated form of stem cells, which are produced from an existing adult cell, such as from hepatocytes, fibroblasts, keratinocytes, and neurons. The main derived cell types of induced pluripotent cells are hepatocytes, fibroblasts, keratinocytes, amniotic cells, and others. Hepatocytes are the liver's primary functional cells, performing a staggering array of metabolic, endocrine, and secretory tasks. The various application includes academic research, drug development, and discovery, toxicity screening, and regenerative medicine and are used in several sectors such as hospitals, and research laboratories. The global induced pluripotent stem cell (iPSC) market is segmented - 1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Other Derived Cells 2) By Application: Academic Research, Drug Development And Discovery, Toxicity Screening, Regenerative Medicine 3) By End-User: Hospitals, Research Laboratories The global induced pluripotent stem cell (ipsc) market size will grow from $2.69 billion in 2022 to $2.97 billion in 2023 at a compound annual growth rate (CAGR) of 10.5% . The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global induced pluripotent stem cell (ipsc) market is expected to grow to $4.36 billion in 2027 at a CAGR of 10.1% . An increase in the prevalence of chronic disorders is one of the major factors that is driving the growth of the Induced pluripotent stem cell market. Chronic disorders like heart disease, cancer, stroke, diabetes can be treated with Induced pluripotent stem cell. Induced Pluripotent stem cells are taken from any tissues from a child or an adult and are genetically modified to behave like embryonic stem cells. According to the report published by Partnership to Fight Chronic Disorder (PFCD), it was found that out of 133 million Americans, 45% of the population had at least one chronic disorder. Moreover, it was estimated that 7 out of 10 deaths in the USA, which is approximately 1.7 million, are due to chronic disorders and these deaths can be controlled by induced pluripotent stem cell treatment. This rise in incidences of chronic diseases is driving the demand for induced pluripotent stem cell treatment market. Major players in the induced pluripotent stem cell (iPSC) market are Thermo Fisher Scientific Inc., FUJIFILM Holdings Corporation (Cellular Dynamics), Takara Bio Inc., Astellas Pharma Inc., Fate Therapeutics, ViaCyte, StemCells, Japan Tissue Engineering Co. Ltd., Fate Therapeutics and Japan Tissue Engineering Co . The potential risk of tumour is one of the major restraints on the growth of the Induced pluripotent stem cell market. As per a scientific research, it was found that there might be a chance of getting cancer from the treatment and people are unwilling to take treatment through Induced pluripotent stem cell therapy. According to the report by American Association for cancer research, in most of the cases while doing the experiment it was found that the occurrence of the tumours was prevalent after a short period of time. This risk of developing a tumour due to Induced pluripotent stem cell therapy is limiting the number of patients opting for this treatment, thereby restraining the growth of the market. Companies in the Induced Pluripotent stem cell market are looking for opportunities for strategic partnerships and collaborations that will help these companies to enter into new geographies and to expand product portfolios. For example, in January 2022, Bristol Myers Squibb and Century Therapeutics entered into a strategic collaboration to develop iPSC-derived allogenic cell therapies for the treatment of acute myeloid leukemia and multiple myeloma. Furthermore, in May 2022, Evotec and Sernova announced strategic partnership to develop iPSC-based beta cell replacement therapy for treatment for type 1 and type 2 diabetes. National Institute of Health (NIH), a part of Department of Health and Human Services, regulates the market for Induced Pluripotent stem cells (iPSC) in the US. If a company is using, making or planning to acquire iPSCs, they are required to provide some information. For instance, a complete and signed copy of the IPSC checklist must be submitted. Any acquisitions in the IPSC’s must obtain approval from the Institutional review board (IRB), the signed approval documents must be attached to the checklist. If the IPSC lines are purchased from an outside or commercial source these agreement documents must also be attested by the IRB and attached. The IPSC’s must be generated by the Intramural Research Program (IRP) under a signed contract before they can be used for any further experimentation. In August 2021, catalant, a Us-based pharmaceutical company, acquired RheinCell Therapeutics GmbHfor an undisclosed amount. The acquisition will help Catalent to grow in the cell and gene therapy vertical and develop therapies based on induced pluripotent stem cells. RheinCell Therapeutics GmbH is a Germany-based developer of human induced pluripotent stem cells (iPSCs) for next generation cell therapies. North America was the largest region in the induced pluripotent stem cell (iPSC) market in 2022. Western Europe was the second largest region in the global induced pluripotent stem cell (iPSC) market share. The regions covered in the global induced pluripotent stem cell (iPSC) market report analysis are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the induced pluripotent stem cell (iPSC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The induced pluripotent stem cell (iPSC) market research report is one of a series of new reports from The Business Research Company that provides induced pluripotent stem cell (iPSC) market statistics, including induced pluripotent stem cell (iPSC) industry global market size, regional shares, competitors with an induced pluripotent stem cell (iPSC) market share, detailed induced pluripotent stem cell (iPSC) market segments, market trends and opportunities, and any further data you may need to thrive in the induced pluripotent stem cell (iPSC) industry. This induced pluripotent stem cell (iPSC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Stem cells are autologous or allogenic cells that can differentiate into various types of cells in vivo and in vitro.They aid in medical treatment of injuries and organ damage. The main product types of stem cell are adult stem cell, human embryonic stem cell, induced pluripotent stem cell and others. Adult stem cells are a rare population of cells found in the body for the majority of postnatal life that give rise to a limited number of mature cell types that form the tissue in which they dwell. The different sources include autologous, allogeneic and are used in various applications such as regenerative medicine, drug discovery, and development. The global stem cell market is segmented - 1) By Source: Autologous, Allogeneic 2) By Product Type: Adult Stem Cell, Human Embryonic Stem Cell, Induced Pluripotent Stem Cell, Other Products 3) By Application: Regenerative Medicine, Drug Discovery And Development The global stem cell market grew from $12.72 billion in 2022 to $13.97 billion in 2023 at a compound annual growth rate (CAGR) of 9.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The stem cell market is expected to grow from $20.67 billion in 2027 at a CAGR of 10.3%. There is an increase in the prevalence of Chronic diseases worldwide which drives the Stem cell market. Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use. Currently, widely used stem cell treatment is the transplantation of blood stem cells to treat diseases and conditions of the blood and immune system, or to restore the blood system after treatments for specific cancers. According to WHO, in 2020, prevalence of chronic disease increased to 57%. As the prevalence of chronic disease increases, people opting for the stem cell-based treatment will rise, thus driving the market going forward. Currently, approximately 26,000 patients are treated with blood stem cells in Europe each year. Major players in the stem cell market are Anterogen Co., Ltd., Mesoblast Ltd., Osiris TherapeuticsInc., AlloSource, Cellular Engineering Technologies, BIOTIMEInc., Astellas Pharma USInc., Vericel, RTI SurgicalInc. and Takara Bio Company. The low acceptance rate for stem cell therapy treatments is restraining the growth of the stem cell market. The acceptance rate is particularly low in the Embryonic stem cell therapeutics. Most of these stem cell therapies are yet to be proven in clinical trials and are highly experimental. Due to the nature of these unproven treatments, patients are reluctant to take up these therapies as they present serious health, personal and financial issues. For example, if a person undergoes an unproven or experimental treatment it might make that person ineligible for future clinical trials or treatment options. For instance, in USA, an unproven stem cell offering three elderly women were blinded after getting stem cells derived from fat tissue, at a clinic in Florida These factors are limiting the number of people opting for stem cell therapies, thus restraining the growth of the stem cell market. Companies in the stem cell therapeutics market are focusing on development of new technologies such as the Induced Pluripotent Stem Cells (IPSC) to boost the efficiency of stem cell therapies. IPSC are obtained from blood or skin cells that are reprogrammed to an embryonic-like pluripotent state by incorporating genes that are essential for maintaining key properties and growth of an unlimited source of any kind of human cell required for stem cell therapeutic purposes. These IPSC's are not derived from human embryos, which removes the bioethical issues, thus allowing scientists to obtain federal funding and support easily. A Japanese company, Oksara opened a medicine center that produced cells derived from iPS Cells. Similarly, Takar Bio company launched human iPSC derived Beta Cells i.e., Cellartis for disease modeling and drug discovery. The Food and Drug Administration's Centre for Biologics Evaluation and Research (CBER) is the regulator in the US, for human cells, tissues, and cellular and tissue-based products (HCT/P) intended for implantation, transplantation, infusion or transfer into a human recipient, including hematopoietic stem cells. There are certain protocols that the FDA has established, for example, the current good tissue practice, donor screening and donor testing requirements which are in place to prevent the transmission of any communicable diseases. The stem cells come from different sources (bone marrow, umbilical cord blood or peripheral blood) and have different applications. Licenses are required to distribute and market these products. In August 2021, Catalent, a US-based provider of advanced delivery technologies, development, and manufacturing solutions for pharmaceuticals, biologics, and cell and gene treatments acquired RheinCell Therapeutics GmbH for an undisclosed amount. With this acquisition Catalent aims to deploy RheinCell's expertise and deep knowledge in iPSC cell lines that will boost Catalent’s cell therapy portfolio, allowing them to offer iPSC banks to their customers as a premium source for their therapeutic development pathway. RheinCell Therapeutics GmbH is a Germany based company that specializes in the GMP-compliant generation of human induced pluripotent stem cells (iPS cells). North America was the largest region in the stem cell market in 2022. Western Europe was the second largest region in the global stem cell market share. The regions covered in the global stem cell market market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the stem cell market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The stem cell market consists of sales of organoids & 3D Cell Culture, mesenchymal Stem Cells, neural stem cells, hematopoietic stem cells, and cancer stem cells. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The stem cell market market research report is one of a series of new reports from The Business Research Company that provides stem cell market market statistics, including stem cell market industry global market size, regional shares, competitors with a stem cell market market share, detailed stem cell market market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell market industry. This stem cell market market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell culture refers to the growth of human, plant, or animal cells in a lab, as well as the growth of microorganisms like bacteria and yeast. Cell cultures can be used for research, medication testing, and infection diagnosis. The cells may come from multicellular eukaryotes, established cell strains, established cell lines, or any combination of these. The main types of cell culture are primary cell culture, secondary cell culture, and cell line. Primary cell cultures are those that develop from tissue explants or specific cells extracted from the source tissue. The different media include natural and artificial ones and are used in stem cell technologies, cancer research, biopharmaceuticals, tissue engineering, regenerative medicine, and others. The global cell culture market is segmented - 1) By Type: Primary Cell Culture, Secondary Cell Culture, and Cell Line 2) By Media: Natural, Artificial 3) By Applications: Stem Cell Technologies, Cancer Research, Biopharmaceutical, Tissue Engineering & Regenerative Medicine, Other Applications The global cell culture market grew from $22.49 billion in 2022 to $24.94 billion in 2023 at a compound annual growth rate (CAGR) of 10.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of the global cell culture market is expected to grow from $38.18 billion in 2027 at a CAGR of 11.2%. The rise in demand for cell therapy is expected to drive the cell culture market growth. In cell therapy, viable cells are injected or implanted into a patient's body to cure a medicinal disease. Cell culture is a vital step in any cell-based therapy. According to the Cancer Research Institute (CRI), there are about 1,483 active cell therapies in development in 2020, compared to 1,011 in 2019. Cell culture is used in the development, manufacture, and commercialization of cell therapies and holds the potential to revolutionise the healthcare industry for the treatment of various diseases. Hence, a surge in the demand for cell therapy aids in the growth of the cell culture market. Major players in the cell culture market report are Thermo Fisher Scientific Inc., Corning, Inc., Becton, Dickinson, and Company, Eppendorf AG, Merck KGAA, Lonza Group AG, Sartorius AG, Promocell GmbH, Danaher, and Sartorius. The lack of skilled professionals is expected to hinder the industry growth. The consequence of having unskilled workers can also be detrimental to the bottom line of a company, as even a small batch error can cost an organisation millions of dollars. The regulatory agency that issues the facility's licence requires an annual report that includes all failed batches, and if the failure rate is higher than 5%, the plant may be at risk of losing its ability to sell its drug. Furthermore, in February 2022, the U.S. Bureau of Work Statistics estimated that the pandemic cost the labour force close to 8 million skilled-labor positions. In the sectors in charge of the majority of the nation's transportation, construction, and mechanical needs, nearly half of the vacancies have been filled, but about 4 million still exist. The lack of talent is expected to adversely impact the growth of the cell and gene therapy industry, thereby restraining the growth of the market. The development of products for 3D cell culture by the companies operating in the cell culture market is gaining significant popularity. A 3D cell culture is an artificially created environment in which biological cells are permitted to grow or interact with their surroundings in all three dimensions, similar to how they would in a living organism. For instance, in July 2020, Rigenerand, an Italian company engaged in the production of innovative cell-based technology products for regenerative medicine and oncology, launched a 3D bioreactor called the VITVO handheld bioreactor to offer increased usability, sizing, a closed system, and flexibility for 3D cell culture technologies. Similarly, Jellagen, a UK-based marine biotechnology company, launched JellaGel, a jellyfish collagen hydrogel, suitable for 3D cell culture and tissue engineering. Danaher, a Fortune 500 science and technology company based in the United States, paid $21.4 billion for General Electric Life Sciences' biopharma business in March 2020.As a part of Danaher, the company is to be called Cytiva and will be a standalone operating company within Danaher's Life Sciences segment. GE Biopharma’s offerings included cell culture media, single-use technologies, process chromatography hardware & consumables, development instrumentation and consumables, and service. North America was the largest region in the cell culture market in 2022. The Middle East is expected to be the fastest growing region in the global cell culture market share during the forecast period. The regions covered in the cell culture market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell culture market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell culture market includes revenues earned by entities by diagnosing infections, testing new drugs, and conducting research. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain or as part of other products. The cell culture market research report is one of a series of new reports from The Business Research Company that provides cell culture market statistics, including cell culture industry global market size, regional shares, competitors with a cell culture market share, detailed cell culture market segments, market trends and opportunities, and any further data you may need to thrive in the cell culture industry. This cell culture market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Nanosilica refers to an allotrope of silicon containing 99% silicon dioxide, which lowers the cement volume while finishing the grading of the aggregate mix in the zone of the smallest sizes. This is the second most abundant element in the earth’s crust. The nanosilica market covered in this report is segmented by type into P type, S type, and type III. It is also segmented by raw material into rice husk, olivine, bagasse, and others and by application into rubber, health and medicine, food, coatings, plastic, concrete, gypsum, cosmetics, electronics, and others. The global nanosilica market is segmented - 1) By Type: P Type, S Type, Type III 2) By Raw Material: Rice Husk, Olivine, Bagasse, Other raw Materials 3) By Application: Rubber, Health And Medicine, Food, Coatings, Plastic, Concrete, Gypsum, Cosmetics, Electronics, Other Applications The global nanosilica market size will grow from $3.95 billion in 2022 to $4.28 billion in 2023 at a compound annual growth rate (CAGR) of 8.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global nanosilica is expected to grow to $5.4 billion in 2027 at a CAGR of 6.0%. Increased demand for nanoparticles in the medical industry contributed to the growth of the nano-silica market. Nanoparticles are presently being engaged as a tool to explore the rarest approaches of medical sciences in several ways like imaging, sensing, targeted drug delivery, gene delivery systems, and artificial implants. A replacement study done by Washington University (GW) Cancer Center found that nanoparticle-encapsulated doxorubicin is promising in the treatment of triple-negative carcinoma. Doxorubicin may be a well-known anthracycline drug class used primarily together with chemotherapy. Amino-functionalized silica nanoparticles (SiNPs) are being used as targeted delivery vehicles for the potential treatment of carcinoma. SiNPs can efficiently encapsulate doxorubicin and may be attached to a targeting moiety like anti-Claudin-4 (CLN4). Nanoparticles have been found to help increase the contrast of the image produced by ultrasonography particularly when imaging tumors. The nanoparticles market experiences huge demand from the medical industry, which in turn will propel the revenues generated for the nano-silica market. Major players in the nanosilica market are NanoPore Incorporated, Fuso Chemical, Evonik, Cabot Corporation, DuPont, Akzonobel, Nanostructured and Amorphous Materials (NanoAmor), Wacker Chemie AG, Normet, and NanosilSdn. An increase in the government-sanctioned lockdowns and several manufacturing plants being restricted for an inconsiderable period had impeded the growth of the global nano-silica market. The government shutdown has proved extremely tough for the construction industry which uses nano-silica in its cement-based materials, especially concrete. According to the BLDUP data published in 2020, the government shutdown’s impact on the construction industry was that all the construction projects that were under federal funding ended up losing profits and employee productivity. According to the Congressional Budget Office, the five-week cessation took a meaningful economic toll, costing the USA economy $11 billion, with nearly a quarter of that total invariably lost. Thus, the mass closure of construction industries has negatively affected the growth of the nano-silica market. The launch of 3D printing aerogel microstructures has created immense demand in the nano-silica market. The 3D-printed aerogel micro-structures provide thermal insulation for miniature components. For instance, in 2020, a team of EMPA in Switzerland developed a technique to 3D print microstructures using insulating silica aerogels. The team has clicked in generating stable, well-acclimated microstructures from silica aerogel by utilizing a 3D printer. The printed structures can be as slender as a tenth of a millimetre. The aerogel can be used to insulate small electronic components and even build small pumps and sensors. The thermal conductivity of the silica aerogel is scarcely under 16 mW/(m*K), which is half of that of polystyrene, and even extremely less than that of a non-moving layer of air at 26 mW/(m*K). At an equivalent period of your time, the printed silica aerogel has even more evolved mechanical attributes and may even be riddled and crushed. This exposes completely new feasibilities for the post-processing of 3D-printed aerogel mouldings. U.S. Silica Holdings, Inc., a US-based producer of commercial silica, announced the acquisition of EP Minerals for $750 million. The acquisition is expected to enhance U.S. Silica Holdings, Inc.,’s Oil and Gas businesses. EP Minerals is a US-based producer of Min-u-Sil Ground Silica used in architectural, industrial, traffic paints, and coatings. Asia-Pacific was the largest region in the nanosilica market in 2022. The regions covered in the nanosilica market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the nanosilica market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The nanosilica market consists of sales of solid silica and shaped silica. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The nanosilica market research report is one of a series of new reports from The Business Research Company that provides nanosilica market statistics, including nanosilica industry global market size, regional shares, competitors with a nanosilica market share, detailed nanosilica market segments, market trends and opportunities, and any further data you may need to thrive in the nanosilica industry. This nanosilica market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.